Kristi Rosa | Authors


Sacituzumab Govitecan Prompts Clinical Benefit in Metastatic TNBC, Regardless of Trop-2 Expression

December 11, 2020

Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.

Hematologic Cancers Bear Increased Risk for Adverse COVID-19 Outcomes

December 08, 2020

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.

SY-1425, Azacitidine Combo Demonstrates Clinical Activity in Heavily Pretreated R/R AML

December 08, 2020

A phase 2 trial found that SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.

Atezolizumab Plus Bevacizumab/Chemo Does Not Significantly Improve PFS for Ovarian Cancer

September 26, 2020

The phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial indicated that the addition of atezolizumab to bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.